8 research outputs found
Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension
We studied the hemodynamic, neurohumoral, and biochemical effects of the
novel angiotensin type 1 (AT1) receptor antagonist irbesartan in 86
untreated patients with essential hypertension on a normal sodium diet.
According to a double-blind parallel group trial, patients were randomized
to a once-daily oral dose of the AT1 receptor antagonist (1, 25, or 100
mg) or placebo after a placebo run-in period of 3 weeks. Randomization
medication was given for 1 week. Compared with placebo, 24-hour ambulatory
blood pressure did not change with the 1-mg dose, and it fell (mean and
95% confidence interval) by 7.0 (4.2-9.8)/6.1 (3.9-8.1) mm Hg with the
25-mg dose and by 12.1 (8.1-16.2)/7.2 (4.9-9.4) mm Hg with the 100-mg
dose. Heart rate did not change during either dose. With the 25-mg dose,
the antihypertensive effect was attenuated during the second half of the
recording, and wi
Short- and long-term functional effects of percutaneous transluminal angioplasty in hemodialysis vascular access
The efficacy of percutaneous transluminal angioplasty (PTA) is usually
expressed as the angiographic result. Access flow (Qa) measurements offer
a means to quantify the functional effects. This study was performed to
evaluate the short-term functional and angiographic effects of PTA and to
determine the longevity of the functional effects during the follow-up
period. Patients with an arteriovenous graft (AVG) or an arteriovenous
fistula (AVF) who were eligible for PTA (Qa values of <600 ml/min) were
included. Ultrasound-dilution Qa measurements were obtained shortly before
PTA and periodically after PTA, beginning 1 wk after the procedure. The
short-term effects were expressed as the increase in Qa and the reduction
of stenosis. The long-term effects were expressed as patency and the
decrease in Qa after PTA. Ninety-eight PTA procedures for 60 patients (65
AVG and 33 AVF) were analyzed. Qa improved from 371 +/- 17 to 674 +/- 30
ml/min for AVG and from 304 +/- 24 to 638 +/- 51 ml/min for AVF (both P <
0.0001). In 66% (AVG) and 50% (AVF) of cases, Qa increased to levels of
>600 ml/min. The degree of stenosis decreased from 65 +/- 3 to 17 +/- 2%
for AVG and from 72 +/- 5 to 23 +/- 7% for AVF (both P < 0.005). The
reduction of stenosis was not correlated with DeltaQa (r(2) = 0.066).
Six-month unassisted patency rates after PTA were 25% for AVG and 50% for
AVF. The decreases in Qa were 3.7 +/- 0.8 ml/min per d for AVG and 1.8 +/-
0.9 ml/min per d for AVF. Qa values before PTA and DeltaQa were correlated
with the subsequent decrease in Qa (P < 0.005). In conclusion, Qa
increases after PTA but, in a substantial percentage of cases, not to
levels of >600 ml/min. Qa values before PTA and the increase in Qa were
correlated with long-term outcomes, whereas angiographic results were not.
These data, combined with literature data, suggest that there is optimal
timing for PTA
Serum magnesium and sudden death in European hemodialysis patients
Despite suggestions that higher serum magnesium (Mg) levels are associated with improved outcome, the association with mortality in European hemodialysis (HD) patients has only scarcely been investigated. Furthermore, data on the association between serum Mg and sudden death in this patient group is limited. Therefore, we evaluated Mg in a posthoc analysis using pooled data from the CONvective TRAnsport STudy (CONTRAST, NCT00205556), a randomized controlled trial (RCT) evaluating the survival risk in dialysis patients on hemodiafiltration (HDF) compared to HD with a mean follow-up of 3.1 years. Serum Mg was measured at baseline and 6, 12, 24 and 36 months thereafter. Cox proportional hazards models, adjusted for confounders using inverse probability weighting, were used to estimate hazard ratios (HRs) of baseline serum Mg on all-cause mortality, cardiovascular mortality, non-cardiovascular mortality and sudden death. A generalized linear mixed model was used to investigate Mg levels over time. Out of 714 randomized patients, a representative subset of 365 (51%) were analyzed in the present study. For every increase in baseline serum Mg of 0.1 mmol/L, the HR for all-cause mortality was 0.85 (95% CI 0.77-94), the HR for cardiovascular mortality 0.73 (95% CI 0.62-0.85) and for sudden death 0.76 (95% CI 0.62-0.93). These findings did not alter after extensive correction for potential confounders, including treatment modality. Importantly, no interaction was found between serum phosphate and serum Mg. Baseline serum Mg was not related to non-cardiovascular mortality. Mg decreased slightly but statistically significant over time (Ă„ -0.011 mmol/L/year, 95% CI -0.017 to -0.009, p = 0.03). In short, serum Mg has a strong, independent association with all-cause mortality, cardiovascular mortality and sudden death in European HD patients. Serum Mg levels decrease slightly over time
Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA
Functional renal magnetic resonance imaging (MRI) has seen a number of recent advances, and techniques are now available that can generate quantitative imaging biomarkers with the potential to improve the management of kidney disease. Such biomarkers are sensitive to changes in renal blood flow, tissue perfusion, oxygenation and microstructure (including inflammation and fibrosis), processes that are important in a range of renal diseases including chronic kidney disease. However, several challenges remain to move these techniques towards clinical adoption, from technical validation through biological and clinical validation, to demonstration of cost-effectiveness and regulatory qualification. To address these challenges, the European Cooperation in Science and Technology Action PARENCHIMA was initiated in early 2017. PARENCHIMA is a multidisciplinary pan-European network with an overarching aim of eliminating the main barriers to the broader evaluation, commercial exploitation and clinical use of renal MRI biomarkers. This position paper lays out PARENCHIMA’s vision on key clinical questions that MRI must address to become more widely used in patients with kidney disease, first within research settings and ultimately in clinical practice. We then present a series of practical recommendations to accelerate the study and translation of these techniques
Optimization of the convection volume in online post-dilution haemodiafiltration:practical and technical issues
Nurse practitioner care improves renal outcome in patients with CKD
Treatment goals for patients with CKD are often unrealized for many reasons, but support by nurse practitioners may improve risk factor levels in these patients. Here, we analyzed renal endpoints of the Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of Nurse Practitioners (MASTERPLAN) study after extended follow-up to determine whether strict implementation of current CKD guidelines through the aid of nurse practitioners improves renal outcome. In total, 788 patients with moderate to severe CKD were randomized to receive nurse practitioner support added to physician care (intervention group) or physician care alone (control group). Median follow-up was 5.7 years. Renal outcome was a secondary endpoint of the MASTERPLAN study. We used a composite renal endpoint of death, ESRD, and 50% increase in serum creatinine. Event rates were compared with adjustment for baseline serum creatinine concentration and changes in estimated GFR were determined. During the randomized phase, there were small but significant differences between the groups in BP, proteinuria, LDL cholesterol, and use of aspirin, statins, active vitamin D, and antihypertensive medications, in favor of the intervention group. The intervention reduced the incidence of the composite renal endpoint by 20% (hazard ratio, 0.80; 95% confidence interval, 0.66 to 0.98; P=0.03). In the intervention group, the decrease in estimated GFR was 0.45 ml/min per 1.73 m2 per year less than in the control group (P=0.01). Inconclusion, additionalsupport by nurse practitioners attenuatedthe declineof kidney function and improved renal outcome in patients with CKD. Copyrigh
Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA
Functional renal magnetic resonance imaging (MRI) has seen a number of recent advances, and techniques are now available that can generate quantitative imaging biomarkers with the potential to improve the management of kidney disease. Such biomarkers are sensitive to changes in renal blood flow, tissue perfusion, oxygenation and microstructure (including inflammation and fibrosis), processes that are important in a range of renal diseases including chronic kidney disease. However, several challenges remain to move these techniques towards clinical adoption, from technical validation through biological and clinical validation, to demonstration of cost-effectiveness and regulatory qualification. To address these challenges, the European Cooperation in Science and Technology Action PARENCHIMA was initiated in early 2017. PARENCHIMA is a multidisciplinary pan-European network with an overarching aim of eliminating the main barriers to the broader evaluation, commercial exploitation and clinical use of renal MRI biomarkers. This position paper lays out PARENCHIMA’s vision on key clinical questions that MRI must address to become more widely used in patients with kidney disease, first within research settings and ultimately in clinical practice. We then present a series of practical recommendations to accelerate the study and translation of these techniques